Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma
暂无分享,去创建一个
J. Briones | J. Gribben | S. Montoto | E. González-Barca | P. Abrisqueta | J. Mate | J. Sancho | Antonio Martínez | M. Terol | M. Provencio | B. González-Farré | J. Ribera | M. Alcoceba | M. Baptista | J. Moraleda | G. Tapia | J. Navarro | P. Miralles | M. Morgades | E. Abella | C. García-Ballesteros | A. Muñoz-Marmol | J. Muncunill | F. Vall-llovera | I. Dlouhy | M. Calaminici
[1] Philippe Ruminy,et al. Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay , 2017, Haematologica.
[2] S. Swerdlow. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .
[3] A. Rosenwald,et al. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] L. Staudt,et al. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. López-Guillermo,et al. HIV-infection impact on clinical–biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era , 2015, AIDS.
[6] E. Giné,et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. , 2011, Blood.
[7] Kai Fu,et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Mate,et al. Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection , 2010, Leukemia & lymphoma.
[9] Kai Fu,et al. Recurrent Chromosomal Alterations in Molecularly Classified AIDS-Related Lymphomas: An Integrated Analysis of DNA Copy Number and Gene Expression , 2010, Journal of acquired immune deficiency syndromes.
[10] W. Wilson,et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. , 2010, Blood.
[11] E. Cesarman,et al. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Adrian Wiestner,et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[14] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[15] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.